SUNSHINE BIOPHARMA, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.742 USD | -7.52% |
|
-20.22% | -97.27% |
| May. 21 | Earnings Flash (SBFM) SUNSHINE BIOPHARMA Posts Q1 Revenue $7.5M | MT |
| May. 20 | Sunshine Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Capitalization 1 | 14.45 | 6.972 | 0.7379 | - |
| Enterprise Value (EV) 1 | 14.45 | 6.972 | 0.7379 | 0.7379 |
| P/E ratio | -0.36 x | -1.43 x | -0.74 x | 0.01 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | 0.29 x | 0.02 x | 0.01 x |
| EV / Revenue | - | 0.29 x | 0.02 x | 0.01 x |
| EV / EBITDA | - | - | - | - |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 226 | 257 | 994.5 | - |
| Reference price 2 | 64.00 | 27.15 | 0.7420 | 0.7420 |
| Announcement Date | 4/4/23 | 3/28/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net sales 1 | - | 24.09 | 44.94 | 100 |
| EBITDA | - | - | - | - |
| EBIT 1 | - | -4.785 | -1.043 | 11.06 |
| Operating Margin | - | -19.86% | -2.32% | 11.06% |
| Earnings before Tax (EBT) 1 | - | -4.111 | -0.1534 | 11.99 |
| Net income 1 | -26.74 | -4.506 | -0.2958 | 11.81 |
| Net margin | - | -18.7% | -0.66% | 11.81% |
| EPS 2 | -176.0 | -19.00 | -1.000 | 60.00 |
| Free Cash Flow | - | - | - | - |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 4/4/23 | 3/28/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 5.561 | 5.958 | 7.68 | 7.541 | 9 | 12.6 | 15.8 |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | -0.9896 | -0.7795 | -1.187 | -1.351 | -0.793 | 0.0485 | 1.052 |
| Operating Margin | -17.8% | -13.08% | -15.46% | -17.91% | -8.81% | 0.38% | 6.66% |
| Earnings before Tax (EBT) 1 | -0.8144 | -0.6105 | -1.03 | -1.261 | -0.523 | 0.3185 | 1.313 |
| Net income 1 | -0.9021 | -0.6515 | -1.25 | -1.284 | -0.563 | 0.2785 | 1.273 |
| Net margin | -16.22% | -10.94% | -16.28% | -17.02% | -6.26% | 2.21% | 8.05% |
| EPS 2 | -2.000 | -4.000 | -5.700 | -2.000 | -3.000 | 2.000 | 7.000 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 8/10/23 | 11/13/23 | 3/28/24 | 5/20/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex | - | - | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 4/4/23 | 3/28/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.742
USD
Average target price
15
USD
Spread / Average Target
+1,921.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -97.27% | 738K | |
| +38.51% | 728B | |
| +33.05% | 603B | |
| -6.23% | 360B | |
| +18.78% | 332B | |
| +1.35% | 279B | |
| +16.00% | 244B | |
| +8.09% | 207B | |
| -5.77% | 205B | |
| +6.19% | 164B |
- Stock Market
- Equities
- SBFM Stock
- Financials Sunshine Biopharma, Inc.
